Research Article

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways

Figure 8

Combinatorial treatment with trastuzumab plus brusatol regressed Nrf2/HO-1 and HER2-AKT/ERK1/2 signaling pathways in SK-OV-3 tumor xenografts. (a) Tumors removed from SK-OV-3 xenografts upon treatment with control IgG (15 mg/kg), trastuzumab (15 mg/kg), brusatol (2 mg/kg), or trastuzumab (15 mg/kg) plus brusatol (2 mg/kg) were then subjected to Western blotting to detect the change of a series of proteins involved in Nrf2/HO-1 and HER2-AKT/ERK1/2 pathways. Two representative samples from each treatment group were shown here. (b) Quantification of Western blotting signal intensity analysis is expressed relative to the β-actin loading control by using Image J software. Data show the (three independent experiments); ; ; .
(a)
(b)